ArticleOncotarget2018

Preclinical characterization of tyrosine kinase inhibitor-based targeted therapies for neuroendocrine thyroid cancer.

Karine Pozo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.